2Seventy Bio (TSVT): Surge Following Acquisition Announcement

By Patricia Miller

Mar 12, 2025

1 min read

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Professional asian female scientist works in laboratory using microscope examining chemical samples conducting experiments and analyzing samples advancing studies in vaccine development.

#What You Need to Know

2Seventy Bio Inc (NASDAQ: TSVT) share price surged 77% following Bristol Myers Squibb's announcement of its acquisition for $5 per share in cash. This agreement values the company at approximately $286 million, translating to a hefty premium over its previous closing price at $2.80.

The transaction, expected to be finalized in the second quarter, is still subject to standard closing conditions. Following the completion, 2Seventy Bio shares will cease to be listed on Nasdaq.

Sign up for Investing Intel Newsletter

Get the latest news and updates from our team.

I agree to the privacy policy.

#Why This Is Important for Retail Investors

  • Significant Premium: Investors can benefit from a 78.6% premium from the acquisition offer, enhancing their returns.

  • Strategic Acquisition: The deal highlights Bristol Myers Squibb's strategy to expand its portfolio, which can influence market dynamics.

  • Market Positioning: Acquisitions can lead to stronger market positions, potentially increasing the long-term value of stocks in the sector.

  • Attention to Closing Conditions: Retail investors should be aware of customary closing conditions that may affect the timing and outcome of the transaction.

  • Potential Market Shifts: The acquisition may impact other biotech firms and affect investment strategies across the biotech landscape.

#Relevant ETFs

  • SPDR S&P Biotech ETF

  • iShares Nasdaq Biotechnology ETF

  • First Trust NYSE Arca Biotechnology ETF

  • Invesco Dynamic Biotechnology & Genome ETF

  • ALPS Medical Breakthroughs ETF

  • ARK Genomic Revolution ETF

Invest in a first-in-class, non-invasive skin cancer treatment in a high-demand market.

Related Articles:

Explore more on these topics:

Materials Pharmaceuticals Biotechnology Value Investing Growth Investing Retail investing Stock Market Stocks Quarterly Earnings ETFs Trending Stocks financials Investment Banking and Brokerage Annual Earnings NASDAQ Capital Markets Healthcare

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.